BioMimetic Therapeutics' Augment
This article was originally published in The Gray Sheet
Executive Summary
Synthetic bone graft PMA is on track for review by FDA's Orthopedic and Rehabilitation Devices Panel by early 2011, and approval in mid-2011, according to the company. BioMimetic announced Sept. 8 that a recent meeting with FDA on its PMA, which was filed by the agency in May, raised no "unexpected issues that would impact the timing" for the panel review (1"The Gray Sheet" July 19, 2010). The firm simultaneously announced that its Augment Injectable Bone Graft will also be regulated as a device following a recent Request for Designation submission. BioMimetic says it aims to start a U.S. trial for the injectable formulation of Augment in the fourth quarter, pending investigational device exemption clearance
You may also be interested in...
Financings In Brief
TriVascular raises $60 million: European launch of the firm's Ovation abdominal aortic aneurysm stent graft later this year will be aided by $60 million in new funding led by Pinnacle Ventures, including a "Series C" equity financing and growth capital venture debt, the firm announced July 12. The low-profile stent system is designed to expand the patient population suitable for endovascular aortic repair by addressing a wider range of diseased anatomy, the company explains. European study implants began last March to support a CE mark application, and the firm commenced its U.S. pivotal study in May. A 2008 spinout from Boston Scientific headquartered in Santa Rosa, Calif., TriVascular notes that it also is developing a version of Ovation for thoracic aortic aneurysms (1"The Gray Sheet" April 7, 2008)
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.